- Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
- Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
- Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
- Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
- Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
- Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
- Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
- Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
- Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
- Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
More ▼
Key statistics
As of last trade Purple Biotech Ltd (PPBT:TLV) traded at 15.50, 9.93% above its 52-week low of 14.10, set on Jul 01, 2024.
52-week range
Open | 15.50 |
---|---|
High | 15.50 |
Low | 15.50 |
Bid | 14.90 |
Offer | 15.60 |
Previous close | 15.50 |
Average volume | 308.06k |
---|---|
Shares outstanding | 306.78m |
Free float | 305.72m |
P/E (TTM) | -- |
Market cap | 47.78m ILS |
EPS (TTM) | -0.2679 ILS |
Data delayed at least 20 minutes, as of Jul 16 2024 08:19 BST.
More ▼